Introduction {#s001}
============

Growth differentiation factor 11 (GDF11), one of the members of bone morphogenetic protein/transforming growth factor-β superfamily, is first identified as a regulator of axial skeletal patterning during early embryogenesis, and then found to play a crucial role in various cellular processes, including kidney organogenesis and tissue homeostasis.^[@B1]^ Recently, systemic levels of GDF11 have been shown to decrease with age in several mammalian species, and supplementation of GDF11 reverses age-related cardiac hypertrophy, structural and functional derangements of skeletal muscle, and dysfunction of neurogenesis.^[@B4]^ Furthermore, higher levels of GDF11 and/or its homologue GDF8 are associated with lower risk of cardiovascular events and total mortality in patients with stable ischemic heart disease (IHD).^[@B8]^ These observations suggest that GDF11 may be a circulating rejuvenation factor that restores youthful characteristics in various aged organs, thereby being a novel therapeutic target for antiaging medicine. However, there is some controversy about the pathophysiological role of GDF11 in aging-associated organ damage.^[@B9]^ Indeed, Smith et al. reported that GDF11 did not rescue cardiac hypertrophy in aged mice.^[@B9]^ Moreover, GDF11 has been shown to increase *rather than* decrease with age in both rats and humans, and to inhibit toxin-damaged muscle regeneration in old mice.^[@B10],[@B11]^

Aging process is accelerated in uremia, and aging-related organ derangements, including sarcopenia, cardiac hypertrophy, and impaired cognitive function, are more prevalent in uremic patients.^[@B12],[@B13]^ Therefore, to clarify the pathophysiological role of GDF11 in humans, it is interesting to examine whether circulating levels of GDF11 are decreased or increased in uremic subjects. In this study, we compared serum levels of GDF11 in hemodialysis (HD) patients with those in age-matched healthy controls, and then determined the independent clinical correlates of GDF11 in subjects on HD.

Subjects and Methods {#s002}
====================

Sixty-two maintenance HD patients (34 male and 28 female; mean age, 52.6 years; mean duration of HD, 7.7 months) were enrolled in this study. Patients were dialyzed for 4--5 h with high-flux dialyzers three times a week. Twenty-nine age-matched subjects were used as a control. Blood pressure was measured in the sitting position using an upright standard sphygmomanometer. Blood was drawn from arteriovenous shunt just before starting HD or from the antecubital veins of controls for determination of blood chemistry as described previously.^[@B14]^ GDF11 was measured by a commercially available enzyme-linked immunosorbent assay (ELISA) system (Wuhan EIAab Science Co. Ltd.). Informed consent was obtained from all subjects, and the study protocol was approved by the Institutional Ethics Committees of Kurume University School of Medicine, Japan. This work was conducted in accordance with the Declaration of Helsinki.

Data were presented as mean values ± standard deviation or medians with the interquartile range. The medication for hypertension and dyslipidemia (renin--angiotensin system \[RAS\] inhibitors and statins) and the presence or absence of diabetes mellitus were coded as dummy variables. Statistical differences in clinical parameters were determined using Student\'s *t*-test or chi-squared test. Correlations between GDF11 and other clinical variables were determined by a linear regression analysis. To determine the independent determinants of GDF11, multiple stepwise linear regression analysis was performed. Statistical significance was defined as *p* \< 0.05. All statistical analyses were performed with the use of the SPSS system (SPSS, Inc.).

Results {#s003}
=======

[Table 1](#T1){ref-type="table"} shows the clinical variables of subjects. Serum GDF11 levels in HD patients were significantly higher than those in controls (9.4 ± 5.1 pg/mL vs. 7.3 ± 5.9 pg/mL). Hemoglobin, albumin, and low-density lipoprotein cholesterol levels were significantly lower in HD patients, whereas triglycerides, blood urea nitrogen creatinine, uric acid, corrected calcium, phosphate, intact parathyroid hormone, and high-sensitivity C-reactive protein values were higher than in control subjects. The number of HD patients with diabetes or who received RAS inhibitors or statins were 10, 47, and 2, respectively. A statistical significance was demonstrated between GDF11 and hemoglobin (inversely) ([Table 2](#T2){ref-type="table"}). Multiple stepwise regression analysis revealed that hemoglobin (*p* \< 0.001) was a sole independent correlate of GDF11 levels in HD patients (*R*^2^ = 0.168) ([Table 2](#T2){ref-type="table"}).

###### 

**Clinical Characteristics of Subjects**

                                 Controls        HD patients           *p*
  ------------------------------ --------------- --------------------- ---------
  No. of patients                29              62                     
  No. of men/women               4/25            34/28                 \<0.001
  Age (years old)                56.2 ± 3.9      52.6 ± 13.7           0.062
  HD duration (months) (range)                   7.7 ± 5.2 (0.5--23)    
  Body mass index (kg/m^2^)      21.8 ± 2.4      21.5 ± 4.7            0.732
  Systolic BP (mmHg)             131.6 ± 28.50   140.4 ± 22.0          0.114
  Diastolic BP (mmHg)            75.3 ± 20.2     82.6 ± 12.6           0.148
  Hemoglobin (g/dL)              13.6 ± 2.0      11.2 ± 1.3            \<0.001
  Albumin (g/dL)                 4.5 ± 0.2       3.6 ± 0.5             \<0.001
  LDL cholesterol (mg/dL)        120.6 ± 32.2    87.2 ± 30.9           \<0.001
  Triglycerides (mg/dL)          82.3 ± 72.5     128.69 ± 95.6         0.024
  BUN (mg/dL)                    14.0 ± 3.2      59.5 ± 12.0           \<0.001
  Serum Cr (mg/dL)               0.6 ± 0.1       11.4 ± 2.2            \<0.001
  Uric acid (mg/dL)              4.5 ± 1.1       7.4 ± 1.0             \<0.001
  Corrected Ca (mg/dL)           8.8 ± 0.2       9.6 ± 0.9             \<0.001
  Phosphate (mg/dL)              3.6 ± 0.5       5.4 ± 1.1             \<0.001
  Intact PTH (pg/mL)             50.2 ± 12.9     155.2 ± 97.0          \<0.001
  No. of DM (±)                  29/0            52/10                 0.024
  HbA1c (%)                      5.2 ± 0.5       5.1 ± 0.8             0.197
  hsCRP (mg/dL)                  544 ± 785       3704 ± 11681          0.040
  GDF11 (pg/mL)                  7.3 ± 5.9       9.4 ± 5.1             0.043
  Medication                                                           
   RAS inhibitors (±)            29/0            15/47                 \<0.001
   Statins (±)                   29/0            60/2                  0.328

Values are shown as mean ± standard deviation or range.

BP, blood pressure; BUN, blood urea nitrogen; Ca, calcium; Cr, creatinine; DM, diabetes mellitus; GDF11, growth differentiation factor 11; HbA1c, glycated hemoglobin; HD, hemodialysis; hsCRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein; PTH, parathyroid hormone; RAS, renin--angiotensin system.

###### 

**Univariate and Multiple Stepwise Regression Analysis for the Correlates of GDF11 Levels in HD Patients**

                    Univariate   Multiple stepwise regression                            
  ----------------- ------------ ------------------------------ ------- -------- ------- -------
  Age               −0.177       0.047                          0.168                     
  Sex               −0.043       1.315                          0.738                     
  HD duration       −0.151       0.129                          0.249                     
  Systolic BP       −0.104       0.030                          0.422                     
  Body mass index   −0.131       0.140                          0.312                     
  Hemoglobin        −0.447       0.457                          0.001   −0.447   0.457   0.001
  Albumin           −0.041       1.451                          0.754                     
  Triglycerides     −0.138       0.007                          0.284                     
  LDL cholesterol   −0.248       0.021                          0.054                     
  BUN               0.033        0.055                          0.800                     
  Serum Cr          −0.012       0.340                          0.926                     
  Uric acid         −0.106       0.676                          0.412                     
  Corrected Ca      −0.090       0.741                          0.487                     
  Phosphate         −0.037       0.607                          0.778                     
  Intact PTH        0.052        0.007                          0.691                     
  HbA1c             −0.091       0.801                          0.491                     
  DM                −0.115       1.770                          0.372                     
  hsCRP             0.112        0.000                          0.396                     
  RAS inhibitors    −0.202       1.246                          0.407                     
  Statins           0.580        1.550                          0.662                     

*β*, standardized regression coefficients. *R*^2^ = 0.168.

Male = 0, female = 1. Medication (+) = 0, medication (−) = 1.

SE, standard error.

Discussion {#s004}
==========

Cardiac hypertrophy and remodeling as well as impaired regeneration of skeletal muscle and neurons in old mice have been reversed by heterochronic parabiosis.^[@B4]^ Furthermore, circulating levels of GDF11 are decreased with age in several animal species, and supplementation of GDF11 has been shown to rescue these age-related organ damage.^[@B4]^ These observations suggest that GDF11 may be a circulating rejuvenation factor in young mice that could reverse age-related dysfunction of multiple organ systems.^[@B4]^ However, other groups have reported that GDF11 is increased *rather than* decreased with age and that reduced circulating levels of GDF11 are unlikely a rejuvenation factor that reverses age-dependent changes in mouse heart, skeletal muscle, and brain.^[@B9]^ Therefore, to further examine the pathophysiological role of GDF11 in human aging process, we chose uremic patients and measured their GDF11 levels in this study because age-related organ damage is accelerated under uremic conditions.^[@B12],[@B13]^

We demonstrated here for the first time that circulating GDF11 levels were significantly increased in HD patients than in age-matched controls and that age was not associated with GDF11 levels in uremic subjects. Recently, Fadini et al. reported that compared with control subjects, diabetic patients had significantly increased plasma GDF11 values, especially those with macroangiopathy.^[@B15]^ Moreover, they showed that there was no correlation between age and GDF11 in type 2 diabetic subjects.^[@B15]^ These findings were in striking contrast with the observation in the Heart and Soul and HUNT3 cohorts, showing that GDF11/8 values were lower in older participants and inversely associated with increased risk of cardiovascular events and overall morality in patients with IHD.^[@B8]^ As the case with uremia, given that diabetes is characterized with accelerated aging and increased risk for cardiovascular disease,^[@B16],[@B17]^ kinetics and regulation of circulating GDF11 may differ between normal physiological aging process and accelerated pathological aging conditions, such as uremia and diabetes. Elevation of GDF11 levels in uremic patients could be attributed to impaired clearance by HD, which may work as a counter-system against accelerated aging-related organ damage in patients with HD. Another possibility is that difference of reagents and/or methods used for assaying GDF11 could account for the discrepant results (modified aptamer-based proteomic platform in the Heart and Soul and HUNT3 cohorts vs. ELISA in Fadini\'s and our subjects).

In this study, we also found that low hemoglobin values were independently associated with high GDF11 levels in HD patients. GDF11 has been shown to inhibit erythroid maturation in mice both *in vivo* and *ex vivo*.^[@B18],[@B19]^ So increase of GDF11 levels may be involved in erythropoietin-resistant anemia, which is often observed in uremic patients.^[@B20]^ Since a poor initial hematopoietic response to erythropoietin is associated with adverse cardiovascular events in diabetic patients with uremia,^[@B20]^ pharmacological upregulation and/or supplementation of GDF11 may not exert beneficial effects on aging-related disorders, such as cardiovascular disease in HD patients.

Limitations {#s005}
===========

There are some limitations in this study. This study was cross-sectional and thus could not assess the questions of whether elevation of GDF11 was a cause or consequence of uremia or anemia. The small sample size is limited for subgroups analysis with solid results. Hemoglobin levels in HD patients are influenced by therapies, such as administration of erythropoiesis-stimulating agents and iron. Therefore, various comedications may limit and confound the present findings. Thus, a further study will be needed to address whether supplementation of GDF11 could be functionally correlated with uremia-related organ dysfunction.
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